Clinical analysis of de novo malignancies in recipients after renal transplantation
10.3969/j.issn.1674-7445.2018.01.010
- VernacularTitle:肾移植受体术后新发恶性肿瘤临床分析
- Author:
Jiang LI
1
;
Xuchun CHEN
;
Yiman MENG
;
Lei YANG
Author Information
1. 中国医科大学附属第一医院肝胆外科暨器官移植科
- Keywords:
Renal transplantation;
Malignancy;
de novo;
Urinary system;
Immunosuppressive agents;
Surgical resection;
Radiotherapy;
Chemotherapy;
Renal carcinoma;
Bladder carcinoma;
Lung carcinoma
- From:
Organ Transplantation
2018;9(1):69-73
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the characteristics and treatment methods of de novo malignancies in recipients after renal transplantation. Methods Clinical data of 43 patients with de novo malignancies after renal transplantation among 759 recipients were analyzed retrospectively. Characteristics, treatment methods and prognosis of the de novo malignancies after renal transplantation were summarized. Results The incidence of de novo malignancies in recipients after renal transplantation was 5.7％. The age of onset was (52±11) years old, and the de novo malignancies was diagnosed in 13-193 months with the median of 60 months after renal transplantation. The 43 patients with de novo malignancies included 9 cases of primary renal carcinoma, 7 cases of bladder carcinoma, 6 cases of lung carcinoma, 5 cases of lymphoma, 4 cases of colorectal carcinoma, 4 cases of mammary carcinoma, 2 cases of skin carcinoma, 1 case of adrenal carcinoma, 1 case of gastric carcinoma, 1 case of primary carcinoma of liver, 1 case of pancreatic carcinoma, 1 case of scalp angiosarcoma and 1 case of meningioma, and they were treated by surgical procedure, adjusting immunosuppressive therapy, radiotherapy or chemotherapy after diagnosed. The postoperative 1- and 5-year survival rates were 81％ and 63％, respectively. Conclusions The incidence of de novo malignancies in recipients after renal transplantation is higher than that in healthy subjects, and urological neoplasm is most common. Radical resection should be considered first, and antineoplastic combined therapy can be performed for the patients who cannot undergo surgery. Meanwhile, dosage of immunosuppressive agents can be reduced and medication regimens can be adjusted, thus effectively prolonging the survival time of patients.
